[4-(3-bromo-propoxy)-phenyl]-acetic acid ethyl ester | 116355-01-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: [4-(3-bromo-propoxy)-phenyl]-acetic acid ethyl ester
• 英文别名: [4-(3-Bromo-propoxyl)-phenyl]-acetic acid ethyl ester；ethyl 2-[4-(3-bromopropoxy)phenyl]acetate
• CAS: 116355-01-2
• 化学式: C₁₃H₁₇BrO₃
• 分子量: 301.18
• InChiKey: XMCJTXYIVCFXEG-UHFFFAOYSA-N

物化性质

• 沸点：
  372.6±27.0 °C(Predicted)
• 密度：
  1.315±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [4-(3-bromo-propoxy)-phenyl]-acetic acid ethyl ester 在 potassium carbonate 、 一水合肼 、 potassium iodide 作用下， 以 乙醇 、 丁酮 为溶剂， 反应 2.0h， 生成 (4-{3-[2-Ethyl-5-hydroxy-4-(1H-pyrazol-3-yl)-phenoxy]-propoxy}-phenyl)-acetic acid ethyl ester
  参考文献：
  名称：

  Leukotriene B4 (LTB4) Receptor Antagonists: A Series of (Hydroxyphenyl)pyrazoles

  摘要：

  A series of (hydroxyphenyl)pyrazoles was designed by molecular modeling comparison with the LTB(4) structure and prepared for evaluation as LTB(4) receptor antagonists, culminating in 4-ethyl-5-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]-2-(1H-pyrazol-3-yl)phenyl (2). Using an assay for inhibition of specific [H-3]LTB(4) binding to human PMN, it was found that the pyrazole ring could be methylated at N(1) with little loss of activity while methylation at N(2) reduced activity significantly. The structure-activity relationship of the terminal acid group was investigated. Good activity was found with o- and m-phenylalkanoic acids, chromane carboxylic acid, and tetrazole groups. The best in vitro activity was realized with the pyrazole nitrogen unsubstituted and with a six-carbon chain linking the phenyl ether oxygen to the tetrazole group. Compound 2, having an IC50 of 6.4 +/- 0.8 nM in the binding assay, was selected for further preclinical evaluation.

  DOI：

  10.1021/jm00041a021
• 作为产物：
  描述：

  对羟基苯乙酸乙酯 在 potassium carbonate 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 [4-(3-bromo-propoxy)-phenyl]-acetic acid ethyl ester
  参考文献：
  名称：

  3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors

  摘要：

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调控、调节和/或抑制异常细胞增殖。

  公开号：

  US06559173B1

文献信息

• 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
  申请人：——

  公开号：US20030130328A1

  公开（公告）日：2003-07-10

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及有机分子，能够调节酪氨酸激酶信号转导，以调节、调控和/或抑制异常细胞增殖。
• Modulators of PPAR and methods of their preparation
  申请人：Zhu Yan

  公开号：US20060058301A1

  公开（公告）日：2006-03-16

  The present invention is directed to certain novel compounds represented by Formula (I) and pharmaceutically acceptable salts, solvates, hydrates and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulinemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity and eating disorders.

  本发明涉及由式（I）表示的某些新型化合物及其药学上可接受的盐、溶剂化合物、水合物和前药。本发明还涉及制备和使用这种化合物的方法，以及含有这种化合物的药物组合物，用于治疗或控制由PPAR介导的多种疾病，如葡萄糖代谢、脂质代谢和胰岛素分泌，特别是2型糖尿病、高胰岛素血症、高脂血症、高尿酸血症、高胆固醇血症、动脉粥样硬化、一种或多种心血管疾病风险因素、X综合症、高三酰甘油血症、高血糖症、肥胖症和进食障碍。
• MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION
  申请人：ZHU Yan

  公开号：US20100087468A1

  公开（公告）日：2010-04-08

  The present invention is directed to certain novel compounds represented by Formula (I) and pharmaceutically acceptable salts, solvates, hydrates and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulinemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity and eating disorders.

  本发明涉及一些新型化合物，其由公式（I）表示，以及其药学上可接受的盐、溶剂、水合物和前药。本发明还涉及制备和使用这些化合物的方法，以及含有这些化合物的药物组合物，用于治疗或控制由PPAR介导的许多疾病，例如葡萄糖代谢、脂质代谢和胰岛素分泌，具体包括2型糖尿病、高胰岛素血症、高脂血症、高尿酸血症、高胆固醇血症、动脉粥样硬化、一种或多种心血管疾病的风险因素、X综合症、高三酰甘油血症、高血糖、肥胖和进食障碍。
• [EN] MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION<br/>[FR] MODULATEURS DE PPAR ET LEURS METHODES DE PREPARATION
  申请人：METABOLEX INC

  公开号：WO2006020916A3

  公开（公告）日：2006-06-01
• US6559173B1
  申请人：——

  公开号：US6559173B1

  公开（公告）日：2003-05-06